Risk factors for death after sepsis in patients immunosuppressed before the onset of sepsis

Scandinavian Journal of Infectious Diseases

Volumn 41, Issue 6-7, 2009, Pages 469-479

  Poutsiaka, Debra D ^a   Davidson, Lisa E ^a   Kahn, Katherine L ^b   Bates, David W ^c   Snydman, David R ^a   Hibberd, Patricia L ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOODSTREAM INFECTION; CLINICAL FEATURE; CONTROLLED STUDY; DEATH; FEMALE; HOSPITAL INFECTION; HUMAN; HYPOTHERMIA; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; NEGRO; NEOPLASM; PREDICTOR VARIABLE; RIGOR; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SURVIVAL;

AGE FACTORS; AGED; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS; SEPSIS;

EID: 72149091697     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540902962756     Document Type: Article

References (41)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. New England Journal of Medicine 2003;/348:/1546-54.
2. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. (see comment.) Chest. 1992;/101:/1644-55.
3. Centers for Disease C, Prevention. Epidemiology of HIV/ AIDS-United States, 1981-2005. MMWR Morbidity & Mortality Weekly Report 2006;55:589-592
4. Angus DC, Wax RS. Epidemiology of sepsis: an update. Critical Care Medicine 2001;29 (Suppl 7):S109-S116.
5. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, et al. Epidemiology of sepsis and infection in ICU patients from an international multicenter cohort study.(erratum appears in Intensive Care Med 2002;28:525- 6). Intensive Care Medicine 2002;/28:/108-21.
6. Annane D, Bellissant E, Cavaillon JM, Annane D, Bellissant E, Cavaillon J-M. Septic shock. Lancet (Review) 2005;/365:/ 63-78.
7. Cinel I, Opal SM, Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a primer. Critical Care Medicine (Review) 2009;/37:/291-304.
8. Cohen J. The immunopathogenesis of sepsis. Nature (Review) 2002;420:885-891
9. Kox WJ, Volk T, Kox SN, Volk HD. Immunomodulatory therapies in sepsis. Intensive Care Medicine (Review) 2000;/ 26 (Suppl 1):/S124-8.
10. Monneret G, Venet F, Pachot A, Lepape A, Monneret G, Venet F, et al. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Molecular Medicine (Review) 2008;/14:/64-78.
11. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. (see comment.) JAMA. 1999;/ 282:/561-8.
12. Novotny AR, Emmanuel K, Ulm K, Bartels H, Siewert JR, Weighardt H, et al. Blood interleukin 12 as preoperative predictor of fatal postoperative sepsis after neoadjuvant radiochemotherapy. British Journal of Surgery 2006;/93:/ 1283-1289
13. Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, et al. Epidemiology of sepsis syndrome in 8 academic medical centers. (see comment) JAMA. 1997;/278:/ 234-240
14. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Apache II: a severity of disease classification system. Critical Care Medicine 1985;/13:/818-29.
15. Barnato AE, Alexander SL, Linde-Zwirble WT, Angus DC. Racial variation in the incidence, care, and outcomes of severe sepsis: analysis of population, patient, and hospital characteristics. American Journal of Respiratory & Critical Care Medicine 2008;/177:/279-84.
16. Hosmer D, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons, Inc.; 1989.
17. Hamilton L. Symptoms of multicollinearity. Regression with Graphics. Belmont: Wadsworth, Inc.; 1992. p. 133-136
18. Kleinbaum D, Kupper L, Muller K, Nizam A. Collinearity. In: Kugushev A, editor. Applied Regression Analysis and Other Multivariable Methods, 3rd edn. Pacific Grove: Duxbury Press; 1998. p. 237-245
19. Centor RM. Signal detectability: the use of ROC curves and their analyses. Medical Decision Making 1991;/11:/102-6.
20. Horton N, Lipsitz S. Review of software to fit generalized estimating equations. American Statistician 1999;/53:/160-9.
21. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;/42:/121-30.
22. McNutt L, Wu C, Xue X, Hafner J. Estimating the relative risk in cohort studies and clinical trials of common outcomes. American Journal of Epidemiology 2003;/157:/940-3.
23. Wong DT, Knaus WA. Predicting outcome in critical care: the current status of the Apache prognostic scoring system. Canadian Journal of Anaesthesia 1991;/38:/374-83.
24. Esper AM, Moss M, Lewis CA, Nisbet R, Mannino DM, Martin GS. The role of infection and comorbidity: factors that influence disparities in sepsis. Critical Care Medicine 2006;/34:/2576-82.
25. Williams JF, Zimmerman JE, Wagner DP, Hawkins M, Knaus WA. African-American and white patients admitted to the intensive care unit: is there a difference in therapy and outcome? Critical Care Medicine 1995;/23:/626-36.
26. Polsky D, Jha AK, Lave J, Pauly MV, Cen L, Klusaritz H, et al. Short- and long-term mortality after an acute illness for elderly whites and blacks. Health Services Research (Comparative Study Research Support, Non-US Gov't) 2008;/43:/ 1388-1402
27. Gibot S, Cariou A, Drouet L, Rossignol M, Ripoll L. Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. (see comment) Critical Care Medicine. 2002;/30:/ 969-973
28. Barnes KC. Genetic determinants and ethnic disparities in sepsis-associated acute lung injury. Proceedings of the American Thoracic Society 2005;/2:/195-201.
29. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995;/274:/968-74.
30. Pittet D, Thievent B, Wenzel RP, Li N, Auckenthaler R, Suter PM. Bedside prediction of mortality from bacteremic sepsis: a dynamic analysis of ICU patients. American Journal of Respiratory & Critical Care Medicine 1996;/153:/684-93.
31. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.(see comment.) Critical Care Medicine. 2003;/31:/ 2742-2751
32. Osborn TM, Tracy JK, Dunne JR, Pasquale M, Napolitano LM. Epidemiology of sepsis in patients with traumatic injury. Critical Care Medicine 2004;/32:/2234-40.
33. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nature Medicine (Clinical Trial Research Support, Non-US Gov't) 1997;/3:/ 678-681
34. Kreymann KG, de Heer G, Nierhaus A, Kluge S, Kreymann KG, de Heer G, et al. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. (Comment.) Critical Care Medicine (Comment Meta-Analysis Review). 2007;/35:/2677-85.
35. Nierhaus A, Montag B, Timmler N, Frings DP, Gutensohn K, Jung R, et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Medicine (Research Support, Non-US Gov't) 2003;/29:/646-51.
36. Schefold JC, von Haehling S, Corsepius M, Pohle C, Kruschke P, Zuckermann H, et al. A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a. Shock (Clinical Trial Research Support, Non-US Gov't) 2007;/28:/418-25.
37. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 (see comment) (erratum appears in Crit Care Med 2008;36:1394-6). Critical Care Medicine (Consensus Development Conference Research Support, Non-US Gov't) 2008;/36:/296-327.
38. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis (see comment.). New England Journal of Medicine (Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-US Gov't) 2008;/358:/125-39.
39. NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. New England Journal of Medicine 2009;360:1283-1297
40. Wachter RM, Flanders SA, Fee C, Pronovost PJ, Wachter RM, Flanders SA, et al. Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure. Annals of Internal Medicine 2008;/149:/ 29-32.
41. Yu KT, Wyer PC, Yu KT, Wyer PC. Evidence based emergency medicine/critically appraised topic. Evidence behind the 4-h rule for initiation of antibiotic therapy in community acquired pneumonia. Annals of Emergency Medicine (Review) 2008;/51:/651-62.